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ABSTRACT 
 
BACKGROUND: 
Disentangling the genetic constellation underlying Alzheimer’s disease (AD) is important. Doing 
so allows us to identify biological pathways underlying AD, point towards novel drug targets and 
use the variants for individualised risk predictions in disease modifying or prevention trials. In 
the present work we report on the largest genome-wide association study (GWAS) for AD risk to 
date and show the combined utility of proven AD loci for precision medicine using polygenic risk 
scores (PRS). 
 
METHODS: 
Three sets of summary statistics were included in our meta-GWAS of AD: an Spanish case-
control study (GR@ACE/DEGESCO study, n = 12,386), the case-control study of International 
Genomics of Alzheimer project (IGAP, n = 82,771) and the UK Biobank (UKB) AD-by-proxy 
case-control study (n=314,278). Using these resources, we performed a fixed-effects inverse-
variance-weighted meta-analysis. Detected loci were confirmed in a replication study of 19,089 
AD cases and 39,101 controls from 16 European-ancestry cohorts not previously used. We 
constructed a weighted PRS based on the 39 AD variants. PRS were generated by multiplying the 
genotype dosage of each risk allele for each variant by its respective weight, and then summing 
across all variants. We first validated it for AD in independent data (assessing effects of sub-
threshold signal, diagnostic certainty, age at onset and sex) and tested its effect on risk (odds for 
disease) and age at onset in the GR@ACE/DEGESCO study. 
 
FINDINGS: 
Using our meta-GWAS approach and follow-up analysis, we identified novel genome-wide 
significant associations of six genetic variants with AD risk (rs72835061-CHRNE, rs2154481-
APP, rs876461-PRKD3/NDUFAF7, rs3935877-PLCG2 and two missense variants: 
rs34173062/rs34674752 in SHARPIN gene) and confirmed a stop codon mutation in the IL34 
gene increasing the risk of AD (IL34-Tyr213Ter), and two other variants in PLCG2 and HS3ST1 
regions. This brings the total number of genetic variants associated with AD to 39 (excluding 
APOE). The PRS based on these variants was associated with AD in an independent clinical AD-
case control dataset (OR=1.30, per 1-SD increase in the PRS, 95%CI 1.18-1.44, p = 1.1×10-7), a 
similar effect to that in the GR@ACE/DEGESCO (OR=1.27, 95%CI 1.23-1.32, p = 7.4×10-39). 
We then explored the combined effects of these 39 variants in a PRS for AD risk and age-at-onset 
stratification in GR@ACE/DEGESCO. Excluding APOE, we observed a gradual risk increase 
over the 2% tiles; when comparing the extremes, those with the 2% highest risk had a 2.98-fold 
(95% CI 2.12–4.18, p = 3.2×10-10) increased risk compared to those with the 2% lowest risk (p = 
5.9×10-10). Using the PRS we identified APOE ɛ33 carriers with a similar risk as APOE ɛ4 
heterozygotes carriers, as well as APOE ɛ4 heterozygote carriers with a similar risk as APOE ɛ4 
homozygote. Considering age at onset; there was a 9-year difference between median onset of 
AD the lowest risk group and the highest risk group (82 vs 73 years; p = 1.6×10-6); a 4-year 
median onset difference (81 vs 77 years; p = 6.9×10-5) within APOE e4 heterozygotes and a 5.5-
year median onset difference (78.5 vs 73 years; p = 4.6×10-5) within APOE e4 carriers. 
 
INTERPRETATION: 
We identified six novel genetic variants associated with AD-risk, among which one common APP 
variant. A PRS of all genetic loci reported to date could be a robust tool to predict the risk and 
age at onset of AD, beyond APOE alone. These properties make PRS instrumental in selecting 
individuals at risk in order to apply preventative strategies and might have potential use in 
diagnostic work-up. 
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Introduction  
 
Alzheimer’s disease (AD) is the most common neurodegenerative disorder affecting 
elderly populations worldwide1. A small fraction of the occurrence of AD in patients can 
be explained by rare mutations which cause the autosomal dominant forms of AD (< 
1%)2. For non-familial cases, the genetic contribution to AD risk is estimated to be 
between 60–80%3 and likely consists of a combination of common and rare alleles, each 
with low to moderate effects on AD risk, gene–gene and gene–environmental 
interactions.  
 
Thus far, multiple loci associated with AD have been described next to causal mutations 
in the PSEN1, PSEN2 and APP genes. The most prominent locus, APOE, was detected 
almost 30 years ago using linkage techniques4. APOE allele ɛ4 has a strong effect, 
conferring a threefold increased risk for AD in heterozygous carriers of the ɛ4 allele and 
an 8-to-12-fold risk in the homozygous state5. After a long and unsuccessful search for 
additional AD loci, the development of single nucleotide polymorphism (SNP) arrays 
permitted the design of comprehensive genome-wide association studies (GWAS). 
Successive waves of analysis and meta-analysis with increasing sample sizes have been 
performed to disentangle the genetic background of AD. By combining the information 
from more than 80,000 participants, the International Genetics of Alzheimer’s project 
(IGAP) recently released the largest meta-analysis of case-control studies reported to 
date6. In parallel with this case-control analysis, by-proxy AD case-control datasets of 
Alzheimer’s disease have successfully been used to increase the statistical power of 
previous AD GWAS7. These approaches use the UK Biobank (UKB)8, a cohort study of 
over half a million individuals in the UK in which the history of dementia for the parents 
is used instead of traditional case-control studies9. The by-proxy strategy confirmed the 
loci identified by IGAP and identified additional candidate loci previously undetected by 
conventional case-control approaches9,10. Overall, in addition to APOE, there have to date 
been identified more than 30 loci have been identified to date that modify the risk of 
AD11–16. These signals, combined with ‘subthreshold’ common variant associations, 
account for ~31% of the genetic variance of AD, leaving most of the genetic risk as yet 
uncharacterised17. A meta-study combining all these studies may lead to the identification 
of associations of genetic loci with AD and might help to confirm loci previously 
proposed by proxy-AD strategies but requiring additional validations. Larger GWASs are 
also important to identify the causative variants, pinpoint culprit genes in the AD-
associated genomic regions and identify the biological pathways underlying AD.  
 
In addition to the biological insights, disentangling the genetic constellation of common 
genetic variations underlying AD has clinical relevance. First, genetic associations can 
point towards novel drug targets. One example is the discovery of the TREM2 gene, which 
has led to the development of TREM2 modulators17. These drugs are now being evaluated 
in trials18 in hopes of benefiting patients in the near-distant future. Second, pre-
symptomatic AD patients are increasingly included in treatment or prevention trials. To 
reduce the necessary duration of these costly studies, individuals at high genetic risk of 
developing the disease are included19,20, such as patients carrying a mutation that causes 
familial AD and those carrying an APOE e4 allele are included as high-risk individuals 
in clinical trials18,19. Other common and rare AD loci are neglected, as the effect or 
frequency of the individual loci is often small. The combined effect of all these loci, 
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however, could account for a substantial proportion of variation in risk21. Indeed, 
combining the effects of all currently known variants results in a polygenic risk score 
(PRS) that is associated with conversion of mild cognitive impairment to AD22,23 the 
neuropathological hallmarks of AD, age at onset of disease24–26 and lifetime risk of AD27. 
However, the discovery of more variants associated with AD warrant that PRS are 
updated and again validated. Further it is important to know how diagnostic certainty, age 
at onset and sex influence the effects of the PRS.  
 
Here we aimed to comprehend and expand the knowledge of the genetic landscape 
underlying AD. We first performed a meta-GWAS integrating all currently published 
GWAS case-control data, by-proxy case-control data and the data from the Genome 
Research at Fundació ACE (GR@ACE) study28. We confirm the novel observed 
associations in a large independent replication study. Then constructed an update of the 
PRS and test if the effects of the PRS are influenced by diagnostic certainty, sex and age 
at onset groups. Last, we test if the PRS can be used to identify individuals at highest risk. 
 
Methods 
 
Meta-GWAS of AD 
 
This study utilizes the summary statistics from three AD GWAS: the summary statistics 
calculated from the GR@ACE28 case-control study, the International Genomics of 
Alzheimer project (IGAP)29 case-control study and UKB AD-by-proxy case-control 
study9 (Figure 1).  
 
GR@ACE  
 
The GR@ACE study28 recruited AD patients from Fundació ACE, Institut Català de 
Neurociències Aplicades (Catalonia, Spain) and control individuals from three centres: 
Fundació ACE (Barcelona, Spain), Valme University Hospital (Seville, Spain) and the 
Spanish National DNA Bank Carlos III (University of Salamanca, Spain) 
(http://www.bancoadn.org). Additional cases and controls were obtained from dementia 
cohorts included in the Dementia Genetics Spanish Consortium (DEGESCO)30. At all 
sites AD diagnosis was established by a multidisciplinary working group, including 
neurologists, neuropsychologists and social workers, according to the DSM-IV criteria 
for dementia and the National Institute on Aging and Alzheimer’s Association’s (NIA–
AA) 2011 guidelines for diagnosing AD. In the present study we considered as AD cases 
any individuals with dementia diagnosed with probable or possible AD at any point in 
their clinical course. For further details on the contribution of the sites, see Supplementary 
Table 1. Written informed consent was obtained from all participants. The Ethics and 
Scientific Committees have approved this research protocol (Acta 25/2016, Ethics 
Committee. H., Clinic I Provincial, Barcelona, Spain).  
 
Genotyping, quality control and imputation  
DNA was extracted from peripheral blood. Genotyping was conducted using the Axiom 
815K Spanish Biobank array (Thermo Fisher) at the Spanish National Centre for 
Genotyping (CeGEN, Santiago de Compostela, Spain) (Supplementary information, 
methods). We conducted previously described standard quality control prior to 
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imputation28. In brief, individual quality control includes genotype call rates > 97%, sex 
checks and no excess heterozygosity; we removed population outliers as well (European 
cluster of 1000 Genomes). We included variants with a call rate > 95%, with minor allele 
frequency (MAF) > 0.01, in Hardy-Weinberg equilibrium (p < 1×10-4 in controls) and 
without differential missingness between cases and controls (Supplementary Table 2, 
Supplementary Figure 1). Imputation was carried out using the Haplotype reference 
consortium31 (HRC, full panel) and the 1000 Genomes reference panel32 (for indels only) 
on the Michigan Imputation server (https://imputationserver.sph.umich.edu). Rare 
variants (MAF < 0.001) and variants with low imputation quality (R2 < 0.30) were 
excluded. Logistic regression models, adjusted for the first four ancestry principal 
components28, were fitted using Plink (v2.00a). Population-based controls were used; 
therefore, age was not included as a covariate (Supplementary Table 3). After quality 
control steps, we included 6,331 AD cases and 6,055 control individuals and tested 
14,542,816 genetic variants for association with AD. 
 
IGAP summary statistics 
 
GWAS summary results from the IGAP were downloaded from the National Institute on 
Aging Genetics of Alzheimer's Disease Data Storage Site (NIAGADS, 
https://www.niagads.org/)29. Details on data generation and the analyses by IGAP have 
been previously described29. In brief, IGAP is a large study based upon genome-wide 
association using individuals of European ancestry. Stage 1 of IGAP comprises 21,982 
Alzheimer’s disease cases and 41,944 cognitively normal controls from four consortia: 
the Alzheimer Disease Genetics Consortium (ADGC), the European Alzheimer's Disease 
Initiative (EADI), the Cohorts for Heart and Aging Research in Genomic Epidemiology 
Consortium (CHARGE) and the Genetic and Environmental Risk in AD Consortium 
Genetic and Environmental Risk in AD/Defining Genetic, Polygenic and Environmental 
Risk for Alzheimer’s Disease Consortium (GERAD/PERADES). Summary statistics are 
available for 11,480,632 variants, both genotyped and imputed (1000 Genomes 
phase1v3). In Stage 2, 11,632 SNPs were genotyped in an independent set of 8,362 
Alzheimer's disease cases and 10,483 controls.  
 
UK Biobank summary statistics 
 
UK Biobank data, including health, cognitive and genetic data, were collected on over 
500,000 individuals aged 37–73 years from across Great Britain (England, Wales and 
Scotland) at the study baseline (2006–2010) (http://www.ukbiobank.ac.uk)33. Several 
groups have demonstrated the utility of self-report of parental history of AD for case 
ascertainment in GWAS (Proxy–AD approach)7,9,10. For this study we used the published 
summary statistics of Marioni et al.9. They included, after stringent quality control, 
314,278 unrelated individuals for whom AD information was available on at least one 
parent in UK Biobank (https://datashare.is.ed.ac.uk/handle/10283/3364). In brief, the 
genetic data of 27,696 participants whose mother had dementia (maternal cases) were 
compared with the 260,980 participants whose mother did not have dementia. Likewise, 
the 14,338 participants whose father had dementia (paternal cases) were compared with 
the 245,941 participants whose father did not have dementia9. The phenotype of the 
parents is independent, and therefore the estimates could be meta-analysed. After 
analysis, the effect estimates were made comparable to a case-control setting. Further 
information on the transformation of the effect sizes can be found elsewhere9,34. The data 
 .CC-BY-NC-ND 4.0 International licenseIt is made available under a 
 is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.was not peer-reviewed)
(whichThe copyright holder for this preprint  . http://dx.doi.org/10.1101/19012021doi: medRxiv preprint first posted online Nov. 15, 2019 ; 
   
 
 
 
7 
 
available comprises summary statistics of 7,794,553 SNPs imputed to the HRC reference 
panel (full panel).  
 
Data analysis 
 
After study-specific variant filtering and quality-control procedures, we performed a 
fixed-effects inverse-variance-weighted meta-analysis35 on the summary statistics 
mentioned above.  
 
To determine the variants with the strongest association per genomic region, we 
performed clumping on SNPs with a genome-wide significant p-value (p < 5×10-8) (Plink 
v1.90, maximal linkage disequilibrium (LD) with R2 < 0.001 and physical distance 1 Mb). 
In the APOE region, the significance level (p ~ 0 for multiple SNPs) interferes with 
clumping; therefore, only the variants determining the APOE ɛ4 and APOE ɛ2 alleles 
were kept in this region36 (rs429358 and rs7412). LD information was calculated using 
the GR@ACE imputed genotypes as a reference. Chromosomal regions associated with 
AD in previous studies were excluded from follow-up (Lambert et al.12, Kunkle et al.6, 
Jansen et al.10). We also performed a functional annotation using FUMA37 (see 
‘Supplementary Methods’). 
 
Confirmation of loci containing novel associations with AD loci 
 
We searched for independent evidence of association with AD for the variants with 
suggestive association (p < 10-5) located in proximity (200 Kb) to nine loci selected for 
follow-up. This strategy was adopted in order to allow for potential refinement of the top 
associated variants during the replication effort. For this confirmatory experiment we 
studied 19,089 AD cases and 39,101 controls not used in the GRA@CE or IGAP studies 
from 16 additional cohorts many of them collected and analysed by the European 
Alzheimer Disease Biobank project (JPND-EADB). See Supplementary Table 3 for 
details of AD cases included in this study and their origin and Supplementary Information 
for descriptions of the replication cohorts). Logistic regression models were fitted with a 
minimum of four principal ancestry components to correct for the population 
substructure. Inverse variance weighted meta-analysis was performed on all datasets in 
both discovery and follow-up stages.  
 
Conditional analyses were performed in regions where multiple variants were associated 
with AD using logistic regression models adjusting for the genetic variants in the region. 
In the chr17-SCIMP region we adjusted rs75511804 for rs72835017, and in the chr16-
PLCG2 region we adjusted rs12444183 for rs3935877 and rs72824905. 
 
Polygenic Risk Scores 
 
Validation of PRS in clinical and pathologically confirmed AD cases 
 
We calculated a weighted individual PRS based on the 39 genetic variants that showed 
genome-wide significant evidence of association with AD in the present study (Figure 2, 
Supplementary Table 4). Selected variants were directly genotyped or imputed with high 
quality (median imputation score R² = 0.93). PRS were generated by multiplying the 
genotype dosage of each risk allele for each variant by its respective weight, and then 
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summing across all variants. We weighted by the effect size from previous IGAP studies 
(Kunkle6 (36 variants), Sims16 (2 variants), Jun38 (MAPT locus), Supplementary Table 4).  
 
We validate the PRS in a sample of 676 AD cases diagnosed based on clinical criteria 
and 332 pathologically confirmed AD cases from the European Alzheimer’s Disease 
Biobank (EADB)–Fundació ACE/Barcelona Brain Bank dataset (EADB–F.ACE/BBB, 
Supplementary information). This dataset was not used in any genetic study. In this 
dataset all pathologically confirmed cases were scored for the presence or absence of 
concomitant pathologies. In all analyses we compared the AD patients to the same 
population-based control dataset (n = 1,386). We performed analyses to test the 
robustness of the PRS. We first tested the effect of adding additional variants below the 
genome-wide significance threshold using a pruning and thresholding approach. For this 
we used the summary statistics of IGAP29 study and we selected independent variants 
using the clump_data() function from the TwoSampleMR package (version 0.4.25). We 
used standard settings for clumping (R2=0.001 and window=1MB) and increasing p-
value thresholds (>1×10-7, >1×10-6, >1×10-5, >1×10-4, >1×10-3, >1×10-2). We tested the 
association of the resulting with clinically diagnosed AD patients and pathologically 
confirmed AD patients. To evaluate the effect of diagnostic certainty we tested if the PRS 
was different between these two AD groups. For the PRS with 39 genome-wide 
significant variants we tested if there were sex-specific effects of the PRS, if the effect 
was different age-of-onset groups of AD and the effect of the PRS in the presence of 
concomitant brain pathologies. 
 
Risk stratification of the validated PRSs 
 
After validation of the PRS we searched for the groups at largest risk of AD in the large 
GR@ACE dataset (6,331 AD cases and 6,055 controls). We stratified the population into 
PRS (percent)tiles taking into account survival bias that is anticipated at old age27. To 
eliminate selection bias calculated the boundaries of the percentiles in the control 
participants aged 55 years and younger (n = 3,546). Based on the boundaries from this 
population the rest of the controls and all AD cases were then assigned into their 
appropriate percentiles. We first explored risk stratification using only the PRSs. For this 
we split the PRSs into 50 groups (2-percentiles) and compared all groups of subjects with 
the group that had the lowest PRS. Secondly, we explored risk stratification considering 
both APOE genotypes and the PRSs. The APOE genotypes were pooled in analyses as 
APOE ɛ22/ɛ23 (n = 998, split into 7 PRS groups), APOE ɛ33 (n = 7,611, split into 25 PRS 
groups), APOE ɛ24/ɛ34 (n = 3,399, split into 15 PRS groups) and APOE ɛ44 (n = 382, 
split into 3 PRS groups). We studied the effect of PRS across groups of individuals 
stratified by APOE genotypes with the lowest PRS group (APOE as the reference group 
using logistic regression models adjusted for four population ancestry components). 
Finally, we compared the median age at onset using a Wilcoxon test. All analyses were 
done in R (version 3.4.2). 
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Results 
 
Genome-wide association study 
 
We performed a meta-analysis of the summary statistics of the GR@ACE study (6,331 
AD cases and 6,055 controls), the IGAP consortium (up to 30,344 AD cases and 52,427 
controls) and the UK Biobank AD-proxy study (27,696 cases of maternal AD with 
260,980 controls and 14,338 cases of paternal AD with 245,941 controls (Figure 1, 
Supplementary Table 3). Although we observed inflation in the resulting summary 
statistics (λ median = 1.08; see Supplementary Figure 2), it was not driven by an 
unmodelled population structure (LD score regression intercept = 1.036). We compared 
the results obtained to a second meta-analysis using only the case-control datasets (IGAP 
Stage 1–2 and GR@ACE datasets as a sensitivity analysis to identify false negative 
results due to possible dilution by the by-proxy approach in the UK Biobank 
(Supplementary Table 5). We identified a genome-wide significant association (p < 5×10-
8) for 36 independent genetic variants in 35 genomic regions and two additional 
suggestive associations. The APOE locus contained two independent signals 
corresponding to the ɛ4 and ɛ2 alleles, respectively. The meta-analysis, including the by-
proxy summary statistics, identified 11 additional loci reaching genome-wide 
significance with respect to case-control-only results. The incorporation of by-proxy 
summary statistics did not show an association in two previously reported AD loci 
(rs7185636-IQCK and rs386572859-MAPT) by the IGAP consortium29,38 and replicated 
in the GR@ACE dataset (OR = 0.93 [0.90-0.95], p = 4.5×10-8 and OR = 0.81 [0.75-0.87], 
p=7.9×10-9, respectively). We observed high correlation between the effect estimates 
from the case-control and by-proxy approach for the significant loci (R2 = 0.994, p = 
8.1×10-37; Supplementary Figure 3).  
 
Among the 36 detected genome-wide significant (GWS) variants, 31 variants (86%) were 
reported in previously published studies or were in complete LD with known AD loci 
(Supplementary Table 5). We followed up the four novel genetic regions. We also 
followed up five genomic regions of interest, which were still awaiting replication 
(PLCG2 and IL-34)9, in incomplete linkage disequilibrium with top SNPs previously 
reported loci10,39 (a locus near the HS3ST120 gene) or showed only suggestive level of 
association (p < 1×10-7; ELK2AP and SPPL2A). We tested all variants in these nine 
genomic loci reaching suggestive level of association (p < 1×10-5) in the replication 
cohorts using 16 independent European-based cohorts (n cases = 19,087 and n controls = 
39,101). In these nine genomic regions we tested 384 variants in the follow-up 
(Supplementary Table 6).  
 
In the follow-up data found association signal in the same direction as the discovery in 
seven out of the nine genomic regions (Table 1, Supplementary Table 6 and 
Supplementary Figures 4–12). We combined discovery and follow-up and found in these 
seven genomic regions, nine independent genetic variants that reached GWS significance 
for association with AD (Table 1). Four of the genomic regions were not previously 
associated with AD and those are marked in the Manhattan-plot (Figure 2). We briefly 
discuss the results below. 
Two genomic regions  contain strong candidate AD genes (APP and SHARPIN) but 
variants in the region had not reached genome-wide significance in earlier meta-
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GWAS15,35. In APP we identified a very common (MAF = 0.46) intronic variant that 
associated with a reduced risk of AD (rs2154481, OR = 0.95 [0.93–0.96], p = 9.3×10-10). 
In SHARPIN we found two missense mutations (p.Ser17Phe and p.Pro294Ser) that are in 
linkage equilibrium (R2 = 1.3×10-6, D' = 0.014 and p = 0.96). The SHARPIN p.Ser17Phe 
(MAF = 0.085) was significant in the discovery as well as the follow-up. In all data 
combined we found the variant associated with a 1.14-fold increased risk of AD 
(rs34173062, 95%CI 1.10–1.18, p = 9.6×10-13). SHARPIN p.Pro294Ser (MAF = 0.052) 
was significant after meta-analysing all data (rs34674752, OR = 1.13 [1.09–1.18], p = 
1.0×10-9). The fourth variant is in a genomic region at chromosome 2, close to the genes 
PRKD3 and NDUFAF7. The variant rs876461 (MAF = 0.143) was borderline significant 
in discovery (OR = 1.07 [1.04-1.09], p = 9.1×10-7) but emerged as the most significant 
variant in the region after in the combined analysis (OR = 1.07 [1.05-1.09], p = 1.3×10-
9). The fifth association was in the 3'-UTR region of CHRNE (Cholinergic Receptor 
Nicotinic Epsilon Subunit). rs72835061 (MAF = 0.085) associated with a 1.09-fold 
increased risk of AD (95%CI 1.06-1.11, p = 1.5×10-10). This variant is relatively close to 
the SCIMP10 locus (333 Kb) and was in weak LD (R2 = 0.139, D' = 0.446 and p < 0.0001) 
with the SCIMP top variant (rs75511804-SCIMP). A conditional analysis, including 
GR@ACE and the independent follow-up (Supplementary Table 7), showed similar 
effect sizes for rs72835017 after adjustment for rs75511804-SCIMP (and vice versa), in 
line with two independent signals that are in weak LD.  
 
We strengthened the evidence of association with AD for three genomic regions. First, 
rs4351014 with AD (combined-OR = 0.94 [0.92-0.95], p = 9.2×10-12). This variant is in 
a gene poor region but has previously been linked to HS3ST1. A stop codon mutation 
(rs4985556, Tyr213Ter, MAF = 0.111) in the interleukin 34 (IL34) gene was previously 
reported to be associated in a by-proxy approach9. We confirmed this associated with an 
increased AD risk in both discovery and follow-up (combined OR = 1.08 [1.06-1.11], p 
= 3.9×10-10). The genomic region that contains the PLCG2 gene has been associated with 
AD twice (the rare missense variant p.P522R in the PLCG2 gene16 and rs12444183 near 
the promotor region of PLCG29). After combination of discovery and follow-up a third 
independent association signal emerged in the PLCG2 region (rs3935877, effect allele 
frequency = 0.868, OR = 0.92 [0.90-0.95], p = 6.9×10-9). We also strengthen the 
association of PLCG2-rs12444183 with AD (MAF = 0.407, combined-OR = 0.95[0.93-
0.96], p = 6.8×10-12). Conditional analyses in the PLCG2 region showed the association 
signal of all three variants (including the missense variant p.P522R in PLCG216) in the 
PLCG2 locus are independent (Supplementary Table 8). 
 
The two loci reaching suggestive evidence of association (Table 1) in the discovery 
(rs7153315-ELK2AP and rs76523702-SPPL2A) did not replicate in the follow-up 
(rs76523702-SPPL2A, p = 0.35) or showed association in the opposite direction 
(rs7153315-ELK2AP, ORdiscovery = 0.94 vs ORfollow-up = 1.16, Table 1). 
 
To link the novel variants to specific genes and functional motifs in their genomic regions, 
we applied different strategies implemented on the FUMA platform (see ‘Supplementary 
Methods’). The selected candidate genes were implicated at least in three mapping 
strategies using this approach (APP, IL34, CHRNE, PLCG2 and SHARPIN, 
Supplementary Tables 9–12, Supplementary Figure 13). 
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Validation of PRS for dementia 
 
In total, after combined meta-analysis, 39 variants have been associated with AD at 
genome-wide significance (excluding the APOE region). We used these 39 variants and 
IGAP weighted effects to construct a PRS (Supplementary Table 4).  
 
The PRS showed a stronger association with the pathologically confirmed AD cases (OR 
= 1.38, per 1-SD increase in the PRS, 95% CI [1.21–1.58]) than with clinical AD cases 
(OR = 1.30, 95%CI [1.18–1.44]) (Figure 3A). However, this difference was not 
statistically significant. We then investigated whether adding additional variants below 
the genome-wide significance threshold would lead to increased performance of the PRS. 
In both pathological and clinical AD cases, the association (as measured by the p-value 
of the effect estimate from logistic regression models) of the PRS decreased when adding 
to PRS variants below the conventional GWAS significance threshold (Figure 3A).  
 
Concomitant brain pathologies were present in 84% of histopathological confirmed cases, 
and the PRS was associated AD cases with all tested concomitant pathologies. The 
strongest risk increase per 1-SD of the PRS was observed with concomitant hippocampal 
sclerosis (OR = 1.67, 95%CI [1.22–2.28]), Figure 3B). The smallest effect for the PRS 
was observed in the 16% of cases that had only AD pathology (OR = 1.22, 95%CI [0.92–
1.61]). The AD patients in our series often had more than one concomitant pathology 
(48.8%), but there was no difference in the effect estimate of the PRS when more than 
one pathology was present (Figure 3B).  
 
Finally, we investigated the differential effect of sex and age at onset on the effect 
estimate of the PRS (Figure 3C). The effect of the PRS was comparable in males (OR = 
1.33 per 1-SD, p = 5.8×10-4) and females (OR = 1.32 per 1-SD, p = 2.5×10-7). Overall, 
there were significant effects of the PRS on AD risk in all five-year age-at-onset groups. 
The strongest effect was observed in the group with an age at onset of 70–75 (OR = 1.58, 
per 1 SD, p = 4.1×10-7).  
 
Risk stratification using polygenic risk scores and APOE 
 
In the independent AD cohort, the PRS of 39 variants showed the strongest association 
with AD (Figure 3). We therefore used this PRS in the large GR@ACE dataset (6,331 
AD cases and 6,055 controls) to identify those at highest genetic risk of AD. Overall, the 
PRS was associated with a 1.27-fold (95% CI 1.23–1.32) increased risk for every standard 
deviation increase in the PRS (p = 7.3×10-39). When we stratified all individuals into 2% 
percentiles of the PRS, we observed a gradual risk increase over the 2% percentile groups 
(Figure 4A, Supplementary Table 13), and when comparing the extremes, those with the 
2% highest risk had a 2.98-fold (95% CI 2.12–4.18) increased risk compared to those 
with the 2% lowest risk (p = 3.2×10-10). 
 
We then studied the ability of the PRS to identify high individuals at risk of the subjects 
within and across APOE genotype groups. The APOE categories were split into PRS 
subgroups depending on number or subjects available: seven PRS groups for the APOE 
ɛ22/ɛ23 genotype, 25 for APOE ɛ33, 15 for APOE ɛ24/ɛ34 and three for APOE ɛ44. 
Within each APOE genotype category we found that the group of individuals with the 
highest PRS score had a higher risk compared to the lowest scored group (Figure 4B). 
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There was a 2.48-fold increased risk for APOE ɛ22/ɛ23 (p = 3.4×10-4), 2.67-fold for 
APOE ɛ33 (p = 3.5×10-9), 2.47-fold for APOE ɛ24/ɛ34 (p = 6.8×10-6) and 2.02-fold for 
APOE ɛ44 (p = 3.4×10-2). The PRS is able to modify the risk associated with APOE such 
that APOE ɛ22/ɛ23 carriers with the highest PRS has a significantly higher risk than 
APOE ɛ33 carriers in the lowest scored group (p = 7.8×10-4), APOE ɛ33 carriers in the 
highest PRS group has a risk comparable to APOE ɛ4 heterozygote carriers with the 
lowest PRS (p = 0.40), and APOE ɛ4 heterozygotes with the highest PRS was not 
significantly different from APOE ɛ4 homozygotes with the lowest PRS (p = 0.68). 
Finally, we compared the risk extremes and found a 16.2-fold (95% CI 8.84–29.5, p = 
1.5×10-19) increased risk for the highest-PRS group compared to the lowest-PRS group 
(the highest PRS APOE ɛ44 group vs the lowest PRS APOE ɛ22/ɛ23 group) 
(Supplementary Table 14).  
 
The stratification of individuals by PRS and APOE genotype also influences age at onset. 
We found a significant (pWilcoxon = 1.7×10-6) difference of 9 years in the median age at 
onset in individuals with the lowest PRS (the median onset is 82 years for APOE ɛ22/ɛ23 
with the lowest PRS) compared with individuals with the highest risk (the median onset 
is 73 years for APOE ɛ44 with the highest PRS risk) (Figure 4C). The PRS did not 
determine age at onset in either APOE ɛ22/ɛ23 (lowest = 82 years, highest = 83 years, 
pWilcoxon = 0.39) or APOE ɛ33 (lowest = 82 years, highest = 81 years, p = 0.16). By 
contrast, in the APOE ɛ4 heterozygotes, the PRS determined a 4-year difference (pWilcoxon 
= 6.9×10-5) in median age at onset between the lowest-risk (81 years) and highest-risk 
(77 years) tiles. Moreover, although the PRS did not have a significant effect on risk 
within APOE ɛ4 homozygotes, it did determine a 5.5-year difference in median age at 
onset (pWilcoxon= 4.6×10-5) between the low-risk (median = 78.5 years) and high-risk (73 
years) tiles.  
 
Discussion 
 
In the present work we report on the largest meta-GWAS for AD risk to date comprising 
genetic information of 467,623 individuals of European ancestry. Using our meta-GWAS 
approach and follow-up analysis, we identified four genomic regions that are significantly 
associated with the risk of AD for the first time (in CHRNE, APP, SHARPIN and near 
PRKD3/NDUFAF7). We also strengthen the association of the PLCG2 region with AD 
by the identification of an additional association signal in the region. This brings the total 
of genetic variants associated with AD to 39 (excluding APOE variants and the very rare 
coding variants). We validated a PRS based on these variants and show that this PRS can 
identify individuals at highest genetic risk of AD independent of APOE. In fact, with this 
PRS we can identify APOE e3 homozygote carriers who have comparable risk for AD as 
APOE e4 heterozygote carriers, as well as APOE e4 heterozygote carriers who have 
comparable risk for AD as APOE e4 homozygotes carriers. We also demonstrate that the 
PRS determines a 4 to 5.5-year age-at-onset difference within APOE e4 carriers. We 
conclude that the PRS of the currently known genetic risk of AD captures important 
differences in AD risk and age at onset. The effects of both risk stratification and age at 
onset are important for research studies and clinical trials.  
 
The work presented builds on a long, ongoing global effort of genetic researchers to 
identify genetic loci associated with AD using family-based studies and genome-wide 
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association studies. We have summarised the landscape of AD genetics of the last 30 
years in Figure 5. We can observe that with the increasing sample sizes across studies, 
more and more variants are found. After review of the literature, we estimate that the 
culprit variant is known in only 15 (40%) out of 39 loci (Table 2). Therefore, much is to 
be gained from candidate gene studies in these other loci. With the current work we have 
added six novel genetic variants in five genetic loci to the landscape; they are discussed 
below. 
The most interesting finding of this work was the confirmation of a very common variant 
in the APP locus (rs2154481, MAF (C-allele) = 0.483). The C-allele of this SNP confers 
subtle protection against AD to the carriers (OR = 0.95 [0.94-0-96], p = 1.39×10-11). The 
genetic marker is in a DNase hypersensitive area of 295 bp (chr21:27473781-27474075) 
probably involved in the transcriptional regulation of the APP gene. Indeed, the variant 
is an eQTL for the APP mRNA and antisense transcript of the APP gene named 
AP001439.2 in public eQTL databases40 (Supplementary Figure 14). Importantly in the 
dorsolateral prefrontal cortex of 726 individuals41, the protective variant increased 
expression of the APP transcript.  
 
Additional functional evidence supporting the role of this region in the modulation of the 
APP transcript has been published recently42. Specifically, Craig et al. describe a block 
of 13 SNPs within the APP locus associated with intellectual abilities in children. This 
LD block, including our top hit for AD (rs2154481), was associated with intelligence (IQ) 
in children from the Avon Longitudinal Study of Parents and Children (ALSPAC, n  = 
 5,165, beta = 1.36, p = 3.5×10-5 for the rs2154481 C-allele). The authors suggest that this 
LD block within APP is involved in the control of gene expression in this locus. Using 
EMSA and luciferase reporter assays, they demonstrate that the C-allele of a linked SNP 
(rs2830077) increased the TFCP2 transcription factor avidity to its binding site and 
increased the enhancer activity of this specific intronic region42. Interestingly, the C-allele 
of the proposed marker (rs2830077) is in high LD with the C-allele of rs2154481 detected 
in our study (LDlink, D'= 0.94, R2 = 0.87, p < 0.0001). The results support increased APP 
gene expression. It is not necessary to mention that the APP locus has been one of the 
major drivers of the classic amyloid hypothesis for AD43,44. Now, our results reconcile 
autosomal dominant and complex Alzheimer disease genetic causality. The 
incontrovertible demonstration of the existence of the common variant within the APP 
associated with sporadic AD and full penetrance mutations affecting autosomal dominant 
AD strongly supports a common causal path. Hence, our results ultimately confirm the 
role of APP physiology in not only early-onset Alzheimer’s disease but also late-onset 
AD, as recently proposed by the IGAP consortium29. Nevertheless, the expression results 
linked to the rs2154481 might appear somehow counterintuitive because increased 
expression of the APP mRNA appeared to be related to disease protection. This could be 
due to potential hormesis or U-effect properties of this locus, where discrete increases of 
the wild-type (non-mutated) APP transcript could be protective and increased expression 
of the mutant gene might be harmful45. The hormesis theory, if true, might help to explain 
the accelerated cognitive deterioration observed in AD patients treated to reduce beta-
amyloid in their brain using beta-secretase inhibitors46,47. An alternative hypothesis 
proposes that rs2154481 mechanisms could be related to the overexpression of protective 
fragments of the APP protein48. Regardless, we feel that more basic research is needed to 
understand the observed association. We are confident that disentangling first the culprit 
variant and then the molecular mechanism associated with rs2154481 hit will help to 
refine the amyloid hypothesis. 
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We found two missense variants in SHARPIN associated with AD. Both variants have a 
relatively large effect (Figure 5), which strongly suggests that SHARPIN is the culprit 
gene in the locus. SHARPIN was proposed as a candidate gene for AD by prioritisation 
of GWAS signals using protein network analysis49 and by genetic association in the 
Japanese population50. In the Japanese study, a rare nonsynonymous variant, 
rs572750141 (NM_030974.3:p.Gly186Arg) was associated at suggestive significance 
with an increased risk of AD. The amino-acid change resulted in aberrant cellular 
localisation of the variant protein and attenuated the activation of NF-κB, a central 
mediator of inflammatory and immune responses. Furthermore, spontaneous mutations 
in the mouse SHARPIN gene resulted in immune system dysregulation51, and rs34173062 
was associated with changes in blood cell indices—specifically myeloid white cell and 
compound white cell52 changes. Our findings confirm SHARPIN as an important AD 
gene, and the effect of the missense mutations on immunity can be directly studied in cell 
models.  
 
We also found a PRKD3/NDUFAF7 signal in our meta-GWAS, but the top hit shifted 
during the overall meta-analysis. Still, the locus retained genome-wide significance, 
requiring future independent replication. It is important to emphasise that it is an excellent 
candidate for further follow-up. The protein kinase D (PKD) family of serine/threonine 
protein kinases occupy a unique position in signalling pathways initiated by 
diacylglycerol and protein kinase C. PKDs are involved in resistance to oxidative stress, 
cell survival, migration, differentiation and proliferation53.  
 
We confirmed an intronic variant in CHRNE gene (rs72835061). Functional analysis of 
the discovery dataset already supported CHRNE as the most likely culprit gene. In fact, 
the rs72835061 variant is a strong eQTL of CHRNE in which the allele C decreases the 
expression in the brain and many other tissues according to GTEx (top differential 
expression in the frontal cortex, p = 2.1×10-13) (Supplementary Figure 15). The CHRNE 
locus encodes the Homo sapiens cholinergic receptor (AChR), nicotinic epsilon, which 
is expressed in muscles and associated with congenital myasthenic syndrome (fast-
channel type)54. Congenital myasthenic syndromes (CMSs) are a group of rare genetic 
disorders of the neurological junction that can result in structural or functional weakness. 
A change in the ε subunit leads to an increase or decrease in AChR protein signalling, 
which impairs cell-to-cell communication in the neuromuscular junction55. The detection 
of a potential hypomorph allele linked to AD risk and affecting cholinergic function could 
re-introduce this neurotransmitter pathway into the search for preventative strategies. 
Further functional studies are needed to consolidate this hypothesis.  
 
For the PLCG2 locus we obtained independent replication for rs12444183 and new 
genome-wide significance for rs3935877. The rare protective missense mutation in 
PLCG216 (p.Pro522Arg) and now two other different haplotypes around PLCG2 
associated with AD reinforce the role of this genomic region in AD susceptibility. The 
dissection of the molecular mechanism behind these potential regulatory variants might 
help to elucidate the gain or loss of the function mechanism of the PLCG2 gene. This 
information could be critical for drug-targeting purposes56.  
 
So far not much attention has gone to a loss-of-function variant (p.Tyr213Ter) in 
interleukin IL34. In a previous AD-by-proxy study, Marioni et al.9 suggested IL34-
rs4985556, but independent replication was pending. Interleukin-34 is a cytokine that 
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promotes the differentiation and viability of monocytes and macrophages through the 
colony stimulating factor 1 receptor (CSF-1R)57. It promotes the release of 
proinflammatory chemokines and, thereby plays an important role in innate immunity 
and inflammatory processes58. Furthermore, microglia treated with IL-34 attenuated the 
oligomeric amyloid-b neurotoxicity in primary neuron-microglia co-cultures59. 
Intracerebroventricular administration of IL-34 ameliorated the impairment of associative 
learning and reduced oligomeric amyloid-b levels in an APP/PS1 transgenic mouse 
model of AD. Therefore, this stop codon could increase the risk of AD by reducing the 
neuroprotective properties of IL34 against the neurotoxicity of oligomeric amyloid-b or 
by modulating microglia reactivity in AD brains. The finding suggests that the generation 
of recombinant IL-34-based therapies could be a promising strategy for combating AD60.  
 
Finally, in this study, we explored the potential utility of the PRS using the extended panel 
of common genetic variants detected. We demonstrated how PRS modifies the risk and 
onset of AD within APOE genotypes. The carriers of high-risk individuals into clinical 
trials is relevant as APOE ε4. The risk modification by the joint effect of common variants 
was most pronounced in APOE ε4 carriers, in whom there was a difference of up to 4 
years in onset age between the low- and high-risk tiles of the PRS in APOE ε34 and a 4.5-
year difference in APOE ε44.  
The added value of PRSs of common variants with small effects in terms of improved 
discrimination between AD cases and controls was reported previously as 
marginal22,26,61,62. Our study and others recently published24,26,27 showed, however, that 
their effects are substantial for risk and age at onset. We show that the PRS could be 
instrumental in clinical diagnosis for AD, the effect of the PRS was similar in men and 
women, and there is risk differentiation at all ages of onset. This shows the wide 
applicability and robustness of PRS. We did not observe that adding a sub-threshold 
signal from GWAS improved the PRS, as had been previously suggested62. The 
identification of subgroups at high genetic risk of AD with an earlier disease onset in the 
general population has important implications for precision medicine. Pathological 
changes related to AD begin to develop up to decades before the earliest clinical 
symptoms63. Therefore, preventive interventions are increasingly introduced in the 
subgroup of individuals with a high genetic risk at a younger age19,20 reducing the duration 
of the trials and thus giving them the opportunity to access the most promising treatments 
for high-risk individuals. In this context, APOE ε4 homozygotes carriers are considered 
high risk, but as shown here the subjects with the highest PRS values and carrying one 
copy of APOE ε4 have a similar risk (Figure 4B). This is relevant as this group represent 
~1% of our control population, the same percentage as all APOE ε4 homozygotes. 
However, further validation on the effect of proposed PRS in longitudinal series of 
healthy and mild cognitive impairment (MCI) subjects, in context of other biomarkers 
(e.g. imaging) are mandatory to determine the predictive utility of this paradigm. With 
continued identification of culprit variants and additional risk loci, we anticipate that the 
precision of PRS will be further enhanced64.   
 
In sum, the current work reinforces the importance of increasing the sample size in future 
meta-analyses to identify novel genetic associations with AD and refine known loci to 
converge on the culprit variants. We described six novel associations with AD of common 
alleles in or near the genes: APP, PLCG2, CHRNE, SHARPIN and PRKD3/NDUFAF7. 
These signals reinforce that AD is complex disease in which amyloid processing and 
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immune response play key roles. We add to the growing body of evidence that polygenic 
scores of all genetic loci to date, in combination with APOE genotypes, are robust tools 
for predicting risk and age at onset of AD. These properties make PRS promising in 
selecting individuals at risk in order to apply preventative strategies.  
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2Figure 1: Flow chart of analysis steps. Discovery meta-analysis in GR@ACE, IGAP stage 1+2 and UKBiobank followed by a replication in 16 independent cohorts. The genome-wide significant signals
found in meta-GWAS were used to perform a Polygenic Risk Score in a clinical and pathological AD dataset. N = total of individuals within specified data set.
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Figure 2: Manhattan plot of overall meta-analysis for genome-wide association in Alzheimer’s disease. 
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Figure 3: Clinical impact of a Polygenic Risk Score for Alzheimer’s Disease
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A. The AD risk of PRS groups compared to those with the 2% lowest risk
B. The AD risk stratified by PRS and APOE risk groups
C. The age at onset of AD stratified by PRS and APOE risk groups
5
Figure 4: Risk of Alzheimer’s disease stratified by Polygenic Risk Score, APOE genotypes, and age at onset stratified by both. 
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6
Figure 5. Landscape for Alzheimer's Disease over the last years. GWAS= Genome-Wide Association Study; OR=Odds Ratio 
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Table 1. Results for the AD loci selected for follow-up 
Chr Closest gene SNP BP Allele 1 Allele 2 FreqA1 OR[CI95%] P OR[CI95%] P OR[CI95%] P
2 PRKD3/NDUFAF7 rs876461 37515958 A G 0.143 1.07[1.04-1.09] 9.14E-07 1.08[1.04-1.13] 3.07E-04 1.07[1.05-1.09] 1.34E-09
8 SHARPIN rs34674752 145154222 A G 0.052 1.11[1.06-1.16] 4.02E-06 1.20[1.10-1.31] 1.65E-05 1.13[1.09-1.18] 1.00E-09
8 SHARPIN rs34173062 145158607 A G 0.085 1.16[1.11-1.21] 1.33E-11 1.09[1.02-1.17] 7.35E-03 1.14[1.10-1.18] 9.62E-13
16 PLCG2 rs3935877 81900853 C T 0.868 0.92[0.90-0.95] 1.12E-07 0.92[0.85-0.99] 1.96E-02 0.92[0.90-0.95] 6.85E-09
17 CHRNE rs72835061 4805437 A C 0.085 1.09[1.06-1.12] 3.92E-09 1.07[1.02-1.12] 7.83E-03 1.09[1.06-1.11] 1.51E-10
21 APP rs2154481 27473875 C T 0.483 0.95[0.93-0.96] 9.26E-10 0.96[0.93-0.99] 3.31E-03 0.95[0.94-0.96] 1.39E-11
4 HS3ST1 rs4351014 11027619 C T 0.684 0.94[0.92-0.96] 5.37E-10 0.93[0.88-0.98] 4.54E-03 0.94[0.92-0.95] 9.16E-12
16 IL34 rs4985556 70694000 A C 0.111 1.08[1.05-1.11] 2.28E-08 1.09[1.03-1.16] 4.59E-03 1.08[1.06-1.11] 3.91E-10
16 PLCG2 rs12444183 81773209 A G 0.407 0.95[0.93-0.97] 1.48E-08 0.92[0.88-0.96] 3.23E-05 0.95[0.93-0.96] 6.81E-12
14 ELK2AP rs7153315 106195719 C G 0.750 0.94[0.92-0.96] 9.80E-08 1.16[1.01-1.33] 0.0412 0.94[0.92-0.97] 9.04E-07
15 SPPL2A rs76523702 51002342 C T 0.802 1.06[1.04-1.08] 6.86E-08 1.02[0.97-1.07] 0.3501 1.05[1.03-1.08] 1.08E-07
Suggestive signals (not replicating)
Variants showing novel genome-wide significant association with AD
Note: FreqA1 is from GR@ACE discovery dataset.  P-value for significance < 5 × 10−8. Effect allele: Allele 1.
Discovery meta-analysis Follow-up datasets Overall
Previously reported genome-wide significant hits replicating in the follow-up
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Table 2. The genetic landscape of late-onset Alzheimer's Disease
RS Chr BP A1/A2 Minor allele MAF Effect OR[CI95%] P-value Top SNP found in Locus priority
Region 
included in 
validation
Closet Gene Culprit variant identified Culprit Gene Other Mutations observed
Certainty 
culprit gene Hit pleitropy
rs4844610 1 2.08E+08 A/C A 0.166 Risk 1.14[1.11-1.16] 7.30E-31 Kunkle et al. 2019 Lambert et al. 2009 No CR1 CNV(linked to hit) CR1 no clear no
rs876461 2 37515958 A/G A 0.143 Risk 1.07[1.05-1.09] 1.34E-09 Present work Present work Yes PRKD3/NDUFAF7 no PRKD3/NDUFAF7 no possible no
rs6733839 2 1.28E+08 T/C T 0.356 Risk 0.84[0.83-0.86] 6.43E-77 Lambert et al. 2013 Seshadri et al. 2010 No BIN1 no BIN1 missense variant clear no
rs10933431 2 2.34E+08 C/G G 0.238 Protective 1.08[1.06-1.10] 3.64E-12 Kunkle et al. 2019 Lambert et al. 2013 No INPP5D no INPP5D no likely no
rs4351014 4 11027619 T/C T 0.316 Risk 0.94[0.92-0.95] 9.16E-12 Present work Desikan al. 2015 Yes HS3ST1 no HS3ST1 no possible no
rs9275152 6 32652196 T/C C 0.068 Protective 0.88[0.85-0.91] 4.17E-16 Present work Lambert et al. 2013 No HLA no HLA-DRB1 no unclear no
rs143332484 6 41129207 T/C T 0.016 Risk 1.08[0.86-1.35] 5.19E-01 Sims et al. 2017 Sims et al. 2017 No TREM2 Missense Arg62His TREM2 missense, nonsense variants clear no
rs75932628 6 41129252 T/C T 0.003 Risk 0.50[0.41-0.60] 6.95E-14 Jonson et al. 2013 Jonson et al. 2013 No TREM2 Missense Arg47His TREM2 missense, nonsense variants clear no
rs9381040 6 41154650 T/C T 0.281 Protective 1.05[1.03-1.07] 3.72E-08 Present work Benítez et al. 2014 No TREML2 no TREML2 no likely no
rs9381564 6 47443806 A/G G 0.278 Risk 0.93[0.91-0.94] 1.79E-15 Present work Lambert et al. 2013 No CD2AP no CD2AP missense variant likely no
rs1859788 7 99971834 A/G A 0.277 Protective 0.92[0.90-0.93] 1.94E-20 Rathore et al. 2018 Hollinworth et al. 2011 No PILRA Missense Gly78Arg PILRA no clear no
rs56402156 7 1.43E+08 A/G A 0.191 Protective 0.92[0.90-0.94] 9.63E-14 Marioni et al. 2018 Lambert et al. 2013 No EPHA1 no EPHA1 missense variant likely no
rs73223431 8 27219987 T/C T 0.384 Risk 0.93[0.91-0.94] 1.94E-17 Kunkle et al. 2019 Lambert et al. 2013 No PTK2B no PTK2B no likely no
rs9331896 8 27467686 T/C C 0.365 Protective 0.90[0.89-0.92] 3.77E-29 Lambert et al. 2013 Harold et al. 2009 No CLU no CLU no likely no
rs34674752 8 1.45E+08 A/G A 0.052 Risk 1.13[1.09-1.18] 1.00E-09 Present work Lancour et al. 2018 yes SHARPIN Missense Pro294Ser SHARPIN missense variant clear Blood cell counts
rs34173062 8 1.45E+08 A/G A 0.085 Risk 1.14[1.10-1.18] 9.62E-13 Present work Lancour et al. 2018 Yes SHARPIN Missense Ser17Phe SHARPIN missense variant clear Blood cell counts
rs7920721 10 11720308 A/G G 0.396 Risk 0.94[0.93-0.96] 3.09E-11 Desikan et al. 2015 Desikan et al. 2015 No ECHDC3 no ECHDC3 no unclear C-reactive protein
rs3740688 11 47380340 T/G G 0.457 Protective 1.07[1.05-1.09] 1.93E-14 Marioni et al. 2018 Huang et al. 2015 No SPI1 no SPI1 no clear no
rs1582763 11 60021948 A/G A 0.379 Protective 0.91[0.90-0.93] 8.69E-24 Jun et al. 2015 Hollinworth et al. 2011 No MS4A4A no MS4A4A no likely C-reactive protein, TREM2 expression
rs3851179 11 85868640 T/C T 0.332 Protective 1.12[1.10-1.14] 3.87E-38 Harold et al. 2009 Harold et al. 2009 No PICALM no PICALM no clear no
rs11218343 11 1.21E+08 T/C C 0.033 Protective 0.83[0.79-0.87] 5.59E-16 Miyashita et al. 2013 Rogaeva et al. 2007 No SORL1 no SORL1 missense variant (incomplete penetrance), LOF variants clear Triglycerides levels
rs17125924 14 53391680 A/G G 0.063 Risk 0.89[0.87-0.92] 6.30E-14 Marioni et al. 2018 Lambert et al. 2013 No FERMT2 no FERMT2 no likely no
rs11623019 14 92936971 T/C T 0.267 Risk 0.93[0.91-0.94] 2.41E-13 Present work Lambert et al. 2013 No RIN3/SLC24A4 no RIN3/SLC24A4 no unclear no
rs593742 15 59045774 A/G G 0.228 Protective 1.08[1.06-1.10] 3.20E-15 Marioni et al. 2018 Kim et al. 2009 No ADAM10 no ADAM10 missense variant (incomplete penetrance) likely no
rs117618017 15 63569902 T/C T 0.165 Risk 0.91[0.89-0.94] 7.98E-11 Jansen al. 2019 Poli et al. 2008 No APH1B Missense Thr27Ile APH1B no likely no
rs7185636 16 19808163 T/C C 0.202 Protective  0.95[0.93-0.97] 2.30E-05 Kunkle et al. 2019 Kunkle et al. 2019 No IQCK no IQCK, KNOP1 yes likely no
rs4985556 16 70694000 A/C A 0.111 Risk 1.08[1.06-1.11] 3.91E-10 Marioni et al. 2018 Marioni et al. 2018 Yes IL34 Stop Gained Tyr213Ter IL34 no clear no
rs12444183 16 81773209 A/G A 0.407 Protective 0.95[0.93-0.96] 6.87E-12 Marioni et al. 2018 Sims et al. 2017 Yes PLCG2 no PLCG2 rare variant Pro522Leu likely no
rs3935877 16 81900853 T/C T 0.132 Risk 0.92[0.90-0.95] 6.85E-09 Present work Sims et al. 2017 yes PLCG2 no PLCG2 rare variant Pro522Leu likely no
rs72824905 16 81942028 C/G G 0.005 Protective 0.72[0.61-0.86] 3.48E-04 Sims et al. 2017 Sims et al. 2017 yes PLCG2 Missense Pro522Leu PLCG2 no clear no
rs75511804 17 5138304 T/C T 0.118 Risk 0.91[0.89-0.93] 6.46E-14 Present work Jansen al. 2019 No SCIMP no SCIMP no possible no
rs2732703 17 46290850 T/G G 0.236 Protective 0.95[0.92-0.97] 1.08E-04 Present work Jun et al. 2015 No MAPT/KANSL1 no KANSL1, MAPT no likely
APOE e4 negative 
and APOE e4 positive 
specific risks
rs4311 17 61560763 T/C C 0.469 Risk 1.06[1.04-1.08] 5.51E-10 Marioni et al. 2018 Alvarez et al. 1999 No ACE Intornic ALU insertion ACE no clear
Intracerebral 
hemorrage 
occurrence in CAA
rs72835061 17 4805437 A/C A 0.085 Risk 1.09[1.06-1.11] 1.51E-10 Present work Present work yes CHRNE/C17orf107 no CHRNE no possible no
rs616338 17 47297297 T/C T 0.008 Risk 1.27[1.14-1.43] 3.22E-05 Sims et al. 2017 Sims et al. 2017 no ABI3 Missense Ser209Phe ABI3 no clear no
rs3752231 19 1043638 T/C T 0.260 Risk 0.92[0.90-0.94] 8.42E-16 Marioni et al. 2018 Hollinworth et al. 2011 No ABCA7 Intronic VNTR ABCA7 rare variants (incomplete penetrance),  LOF variants likely no
rs429358 19 45411941 T/C C 0.168 Risk 3.00[2.93-3.07] 0.00E+00 Strittmatter et al. 1993 Strittmatter et al. 1993 No APOE4 Arg112-Arg158 diplotype APOE no clear
c-reactive protein, 
lipids, platelecrit, 
blood proteins 
levels…
rs7412 19 45412079 T/C T 0.049 Protective 1.58[1.52-1.65] 3.20E-123 Chartier-Harlin et al. 1994
Chartier-Harlin et al. 
1994 No APOE2
Cys112-Cys158 
diplotype APOE no clear
Lipid levels, Blood 
pressure, Blood 
protein levels…
rs12459419 19 51728477 T/C T 0.290 Protective 1.06[1.04-1.08] 3.11E-08 Malik et el. 2013 Bertram et al. 2008 No CD33 Exon 2 splicing modulator CD33 no clear
Blood protein levels, 
platelecrit
rs6024870 20 54997568 A/G A 0.103 Protective 0.90[0.87-0.93] 2.16E-11 Present work Lambert et al. 2013 No CASS4 no CASS4/CSFT1 no unclear no
rs2154481 21 27473875 T/C C 0.483 Protective 0.95[0.94-0.96] 1.39E-11 Present work Goate et al. 1991 Yes APP no APP EOAD full penetrance mutations likely no
Note: Association results of overall meta-GWAS cohorts. Effect allele: A1. Allelic Freq. is from A1 in GR@ACE discovery dataset. LOF: Loss-of-function.
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